Royalty Pharma (RPRX) Aandelenoverzicht
Royalty Pharma plc is actief als koper van biofarmaceutische royalty's en financier van innovatie in de biofarmaceutische industrie in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 5/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 2/6 |
RPRX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Royalty Pharma plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$54.50 |
| 52 Week Hoogtepunt | US$54.64 |
| 52 Week Laag | US$32.21 |
| Bèta | 0.40 |
| 1 maand verandering | 10.37% |
| 3 maanden verandering | 20.04% |
| 1 Jaar Verandering | 67.95% |
| 3 jaar verandering | 68.31% |
| 5 jaar verandering | 35.84% |
| Verandering sinds IPO | 22.47% |
Recent nieuws en updates
Recent updates
Seeking Alpha • May 16
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Narratiefupdate • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Narratiefupdate • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Narratiefupdate • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Narratiefupdate • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Narratiefupdate • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Narratiefupdate • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Analyseartikel • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narratiefupdate • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Analyseartikel • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Narratiefupdate • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Narratiefupdate • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Narratiefupdate • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Narratiefupdate • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Narratiefupdate • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Narratiefupdate • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Narratiefupdate • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Analyseartikel • Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analyseartikel • May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
Royalty Pharma: Massive Opportunity Ahead
Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking AlphaRendement voor aandeelhouders
| RPRX | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 4.7% | 5.3% | 1.1% |
| 1Y | 68.0% | 44.3% | 28.7% |
Rendement versus industrie: RPRX overtrof de US Pharmaceuticals industrie, die het afgelopen jaar een rendement 44.3 % opleverde.
Rendement versus markt: RPRX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 28.7 %.
Prijsvolatiliteit
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: RPRX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van RPRX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc is actief als koper van biofarmaceutische royalty's en financier van innovatie in de biofarmaceutische industrie in de Verenigde Staten. Haar portfolio bestaat uit royalty's op ongeveer 35 op de markt gebrachte therapieën en 20 productkandidaten in ontwikkelingsstadium die zich richten op verschillende therapeutische gebieden, zoals zeldzame ziekten, oncologie, neurowetenschap, infectieziekten, hematologie en diabetes. Het bedrijf heeft een samenwerking voor de financiering van onderzoek en ontwikkeling om de ontwikkeling van JNJ-4804, een onderzoeksgeneesmiddel voor auto-immuunziekten, te bevorderen.
Royalty Pharma plc Samenvatting
| RPRX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$31.38b |
| Inkomsten(TTM) | US$826.29m |
| Inkomsten(TTM) | US$2.44b |
29.2x
Koers/Winstverhouding9.9x
P/S-verhoudingIs RPRX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| RPRX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.44b |
| Kosten van inkomsten | -US$366.18m |
| Brutowinst | US$2.81b |
| Overige uitgaven | US$1.98b |
| Inkomsten | US$826.29m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 1.86 |
| Brutomarge | 115.00% |
| Nettowinstmarge | 33.86% |
| Schuld/Eigen Vermogen Verhouding | 90.1% |
Hoe presteerde RPRX op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
1.7%
Huidig dividendrendement47%
UitbetalingsratioBetaalt RPRX een betrouwbaar dividend?
Zie RPRX dividendgeschiedenis en benchmarks| Royalty Pharma dividenddata | |
|---|---|
| Ex Dividend Datum | May 15 2026 |
| Betaaldatum dividend | Jun 10 2026 |
| Dagen tot Ex-dividend | 11 days |
| Dagen tot dividendbetaaldatum | 15 days |
Betaalt RPRX een betrouwbaar dividend?
Zie RPRX dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 20:38 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Royalty Pharma plc wordt gevolgd door 14 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |